Arterial Inflammation and E-Cigarettes

Arterial Inflammation Clinical Trial

Official title:

Arterial Inflammation and E-Cigarettes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02734888
• Other study ID #: 15-000552
• Status: Completed
• Phase: N/A
• Start date: July 2015
• Est. completion date: February 1, 2023

Study information

• Verified date: October 2023
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Arterial inflammation will be compared using PET scanning in 3 groups: 1) Non-smokers, 2) Tobacco cigarette smokers, 3) Electronic cigarette users.

Description:

Qualified participants will undergo a singe PET/CT to detect arterial inflammation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 1, 2023
• Est. primary completion date: February 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

Healthy

• Nonsmokers OR

• Daily e-cigarette user OR

• Daily tobacco cigarette smoker

Exclusion Criteria:

• Cardiac disease

• Respiratory Disease

• Diabetes mellitus

Related Conditions & MeSH terms

• Arterial Inflammation
• Arteritis
• Inflammation

Intervention

Other:
• No drug or device, only a test. The test is called a PET/CT
A single PET/CT scan will be performed

Locations

Country	Name	City	State
United States	UCaliforniaLA	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	target-to-background ratio (TBR)	TBR will be detected on the scan	intraoperative